Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Total Liabilities
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) has total liabilities worth CN¥2.21 Billion CNY (≈ $323.44 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Jiangxi Fushine Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Jiangxi Fushine Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Jiangxi Fushine Pharmaceutical Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangxi Fushine Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ingenia Communities Group
AU:INA
|
Australia | AU$1.13 Billion |
|
Ruyizhou Inc
NYSE:RYZ
|
USA | $1.80 Billion |
|
Fsilon Furnishing and Construction Materials Corp
SHG:605318
|
China | CN¥229.81 Million |
|
Sino Prima Gas Technology Co Ltd
SHE:300483
|
China | CN¥3.38 Billion |
|
Shunsin Technology Holdings Ltd
TW:6451
|
Taiwan | NT$12.08 Billion |
|
Jamieson Wellness Inc
TO:JWEL
|
Canada | CA$684.21 Million |
|
Shanghai Electric Group Company Limited
F:USR
|
Germany | €247.42 Billion |
|
Titagarh Rail Systems Limited
NSE:TITAGARH
|
India | Rs12.61 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Jiangxi Fushine Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jiangxi Fushine Pharmaceutical Co Ltd (300497) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangxi Fushine Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total liabilities of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.20 Billion ≈ $322.60 Million |
-6.58% |
| 2024-12-31 | CN¥2.36 Billion ≈ $345.33 Million |
+0.50% |
| 2023-12-31 | CN¥2.35 Billion ≈ $343.63 Million |
-0.92% |
| 2022-12-31 | CN¥2.37 Billion ≈ $346.83 Million |
+34.12% |
| 2021-12-31 | CN¥1.77 Billion ≈ $258.59 Million |
+77.09% |
| 2020-12-31 | CN¥997.93 Million ≈ $146.03 Million |
-6.59% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.33 Million |
+1.76% |
| 2018-12-31 | CN¥1.05 Billion ≈ $153.62 Million |
+27.60% |
| 2017-12-31 | CN¥822.70 Million ≈ $120.39 Million |
+33.95% |
| 2016-12-31 | CN¥614.20 Million ≈ $89.88 Million |
+48.56% |
| 2015-12-31 | CN¥413.44 Million ≈ $60.50 Million |
+18.44% |
| 2014-12-31 | CN¥349.09 Million ≈ $51.08 Million |
+12.05% |
| 2013-12-31 | CN¥311.55 Million ≈ $45.59 Million |
+6.80% |
| 2012-12-31 | CN¥291.70 Million ≈ $42.69 Million |
+25.71% |
| 2011-12-31 | CN¥232.04 Million ≈ $33.96 Million |
-- |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more